Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biopharma Asks US Supreme Court Not To Limit Patent Litigation Venue

Executive Summary

Innovators say case before court could upend ANDA litigation by preventing consolidation of cases; Genentech sees potential impact on biosimilar suits.

You may also be interested in...



Biopharma Patent Disputes: Upheaval Likely As US Supreme Court Limits Litigation Venue

Decision requiring suits to be filed in state where defendant is incorporated may deter consolidation of ANDA suits and increase venue fights; Court to hear challenge to PTAB inter partes review process.

Have Patent, Will Travel: Brand Firms Can File Infringement Suits Anywhere

Federal Circuit denies Mylan's bid to dismiss litigation in Delaware; PhRMA, BIO and Teva argued that brand manufacturers should be allowed to sue multiple generic manufacturers in a single forum.

PDUFA Collections Exceeded Target In FY 2021, While GDUFA Fell Short

The US FDA reports that the prescription drug user fee program met 27 of its 29 commitments by the end of FY 2021 and the biosimilar user fee program is on track to meet 16 of 27 of its performance enhancement goals.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS120309

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel